<scp>MYC</scp> overexpression but not <scp>MYC</scp>/<scp>BCL2</scp> double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
Yanjie Wang(First Affiliated Hospital of Zhengzhou University), Qingjiang Chen(First Affiliated Hospital of Zhengzhou University), Shenglei Li(First Affiliated Hospital of Zhengzhou University), Siyu Qian(First Affiliated Hospital of Zhengzhou University), Shanshan Ma(First Affiliated Hospital of Zhengzhou University), Yue Zhang(Guilin Medical University), Mingzhi Zhang(Chinese Academy of Sciences), Meng Dong(First Affiliated Hospital of Zhengzhou University), Pengyuan Wang(Second Military Medical University), Zeyuan Wang(Central South University), Donglin Liu(Boston University), Xiaoyan Feng(Academy of Military Medical Sciences), Xudong Zhang(First Affiliated Hospital of Zhengzhou University), Shuhao Mei(Tianjin University of Technology)
Cited by 6
Related Papers
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
|Bioconjugate Chemistry|2015|302
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
|The Lancet Respiratory Medicine|2022|145
miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42
|Digestive Diseases and Sciences|2011|140